In line with the idea that the observed PAX3/MITF response is a consequence of MAPK-pathway inhibition and as such occurs while patients are still responding to treatment, we found that in tumors from our cohort of patients whose melanoma had progressed, PAX3 and MITF expression were generally reduced and SKI expression was restored (Figures S5E and S5F). Here, MITF is linked to melanoma.